Introduction by Dr. E. Linardou, Metropolitan Hospital Athens, Greece

Dr. E. Linardou gives an overview of the current treatment options for 1L mNSCLC patients.

Patient cases I & II

Leptomeningeal metastases after 1 year PD-L1 inhibitor as consolidation post cCRT (Dr. W. Theelen, Netherlands Cancer Institute, Amsterdam, The Netherlands)
Dr. W. Theelen discusses a 54 year old female patient diagnosed with non-squamous, PD-L1 >1% and KRAS G12C NSCLC. After initial treatment with cCRT + anti-PD-L1, patient presents with brain metastasis. She discusses her approach to choosing the right treatment decision for this mNSCLC patient and the continued management of this patient, including efficacy and safety parameters.

Rapid progression under adjuvant chemotherapy after lobectomy (Prof. L. Decoster, University Hospital Brussels, Belgium)
Prof. L. Decoster discusses a 52 year old male patient diagnosed with squamous NSCLC who undergoes lobectomy. After adjuvant chemotherapy, patient quickly progresses. She discusses her approach to choosing the right treatment decision for this patient with now metastatic disease and PD-L1 <1% and the continued management of this patient, including efficacy and safety parameters (irAE of ulcerative lichen planus).

Panel discussion and Q&A around patient cases I & II

Patient cases III & IV

Progression after concurrant CRT and lobectomy (Dr. W. Theelen, Netherlands Cancer Institute, Amsterdam, The Netherlands)
Dr. W. Theelen discusses a 63 year old female patient with reumatoid arthritis (RA), diagnosed with a non-squamous T3N0M0 NSCLC. After initial neo-adjuvant CRT followed by lobectomy the patient presents with brain metastases. She discusses her approach to choosing the right treatment decision for this mNSCLC patient and the continued management of this patient, including efficacy and safety parameters as well as treatment sequencing for this patient with underlying RA and PS2.

Stage IV disease with KRAS and STK11 mutation in older patient (Prof. L. Decoster, University Hospital Brussels, Belgium)
Prof. L. Decoster discusses a 78 year old female patient diagnosed with non-squamous PD-L1<1% mNSCLC with KRAS G12C and STK11 mutations. She discusses her approach to choosing the right treatment decision for this patient and the continued management of this patient, including efficacy and safety parameters.

Panel discussion and Q&A around patient cases III & IV